Barragán-Campos HM, Jiménez-Zarazúa O, Mondragón JD

Idioma: Ingles.
Referencias bibliográficas: 121
Paginas: 140-157
Archivo PDF: 349.63 Kb.

RESUMEN

sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127: 2893-917.

2. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792-800.

3. Harel R, Angelou L. Spine metastases: current treatments and future directions. Eur J Cancer. 2010;46:2696-707.

4. Pointillar V, Fabre T, Palussière J. [Bone metastases]. Encycl Méd Chyr. 2003;14-798:1-10.

5. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27:165-76.

6. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243-9s.

7. Durand JP, Karoubi P, Anract P, et al. [Bone metastasis: Multidisciplinary management, diagnostic and therapeutic approach]. EMC-Aparato Locomotor. 2013;46:1-16.

8. Kwee TC, Takahara T, Katahira K, et al. Whole-body MRI for detecting bone marrow metastases. PET Clin. 2010;5:297-309.

9. Krishnamurthy GT, Tubis M, Hiss J, et al. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA. 1977;237:2504-6.

10. Georgy BA. Metastatic spinal lesions: State-of-the-art treatment options and further trends. Am J Neuroradiol. 2008;29:1605-11.

11. Scuibba DM, Petteys RJ, Dekutoski MB, et al. Diagnosis and management of metastatic spine disease. A review. J Neurosurg Spine. 2010;13:94-108.

12. Maccauro G, Spinelli MS, Mauro S, et al. Physiopathology of spine metastasis. Int J Surg Oncol. 2011;2011:107969.

13. Oge HK, Aydin S, Cagavi F, et al. Migration of pacemaker lead into the spinal venous plexus: Case report with special reference to Batson´s theory of spinal metastasis. Acta Neurochir (Wien). 2001;143:413-6.

14. Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol. 2005;6:15-24.

15. Barragán-Campos HM, Vallée JN, Lo D, et al. Percutaneous vertebroplasty for spinal metastases: Complications. Radiology. 2006; 238:354-62.

16. Sartor O, Hoskin P, Bruland OS. Targeted radionuclide therapy of skeletal metastases. Cancer Treat Rev. 2013;39:18-26.

17. Collignon J, Gennigens C, Jerusalem G. Assessment of response to therapy for bone metastases: Is it still a challenge in oncology? PET Clin. 2010;5:311-26.

18. Rajarubendra N, Bolton D, Lawrentschuck N. Diagnosis of bone metastases in urological malignancies-- An update. Urology. 2010;76:782-90.

19. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: A review. Crit Rev Oncol Hematol. 2005;56:365-78.

20. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev. 2008;34:92-101.

21. Rosner MH, Dalkin AC. Onco-nephrology: The pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7:1722-9.

22. Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy- A systematic review of randomised trials. Clin Oncol. 2003;15:345-52.

23. Baczyk M. Radioisotope therapy of bone metastases. Nucl Med Rev Cent East Eur. 2011;14:96-104.

24. Saarto T, Janes R, Tenhunen M, et al. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain. 2002;6:323-30.

25. Dunning EC, Butler JS, Morris S. Complications in the management of metastatic spinal disease. World J Orthop. 2012;3:114-21.

26. Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011;61:287-314.

27. Hu MI, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013;105:1417-20.

28. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-9.

29. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77:336-40.

30. Fisher GC, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: An evidencebased approach and expert consensus from the Spine Oncology Study Group. Spine. 2010;35:E1221-9.

31. Molina CA, Gokaslan ZL, Sciubba DM. Diagnosis and management of metastatic cervical spine tumors. Orthop Clin N Am. 2012;43:75-87.

32. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol. 2005;2:504-17.

33. Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastases: A meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21:2604-17.

34. Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252-9.

35. Huang Q, Ouyang X. Biochemical-markers for the diagnosis of bone metastasis: A clinical review. Cancer Epidemiol. 2012;36:94-8.

36. Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: Techniques and recommendations for diagnosis. Lancet Oncol. 2009;10:606-14.

37. Roberts CC, Daffner RH, Weissman BN, et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010;7:400-8.

38. Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): Role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:416-30.

39. Tarnawska-Pier ci ska M, Holody L, Braziewicz J. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG. Nucl Med Rev Cent East Eur. 2011;14:105-8.

40. Baur-Melnyk A. Malignant versus benign vertebral collapse: Are new imaging techniques useful? Cancer Imaging. 2009;9:S49-51.

41. Love C, Din AS, Tomas MB, et al. Radionuclide bone imaging: An illustrative review. Radiographics. 2003;23:341-58.

42. Abikhzer G, Kennedy J, Israel O. 18F NaF PET/CT and conventional bone scanning in routine clinical practice comparative analysis of tracers, clinical acquisition protocols, and performance indices. PET Clin. 2012;7:315-28.

43. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41-55.

44. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977;35:292-8.

45. Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: Diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41:59-67.

46. Beheshti M, Langsteger W. 18 FNaF PET/CT in the assessment of metastatic bone disease: Comparison with specific PET tracers. PET Clin. 2012;7:303-14.

47. Shirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin N Am. 2007;45:669-76.

48. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135-42.

49. Ohta M, Tokuda Y, Suzuki Y, et al. Whole-body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun. 2001;22:875-9.

50. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19:1249-54.

51. Gaeta CM, Vercher-Conejero JL, Sher AC, et al. Metastatic breast cancer PET, PET/CT, PET/MRI:FDG and new markers. Q J Nucl Med Mol Imaging. 2013;57:352-66.

52. Fogelman I. Skeletal uptake of disphosphonate: A review. Eur J Nucl Med. 1980;5:473-6.

53. Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: Review of current treatment options. CA Cancer J Clin. 2008;58:245-59.

54. Vanel D, Dromain C, Tardivon A. MRI of bone marrow disorders. Eur Radiol. 2000;10:224-9.

55. Alyas F, Saifuddin A, Connell D. MR imaging evaluation of the bone marrow and marrow infiltrative disorders of the lumbar spine. Magn Reson Imaging Clin N Am. 2007;15:199-219.

56. Schweitzer ME, Levine C, Mitchell DG, et al. Bull’s-eyes and halos: useful MR discriminators of osseous metastases. Radiology. 1993;188:249-52.

57. Jung HS, Jee WH, McCauley TR, et al. Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR Imaging. Radiographics. 2003;23:179-87.

58. Shah LM, Hanrahan CJ. MRI of spinal bone marrow: part I, techniques and normal age-related appearances. AJR Am J Roentgenol. 2011;197:1298-308.

59. Balliu E, Vilanova JC, Peláez I, et al. Diagnostic value of apparent diffusion coefficient to differentiate benign from malignant vertebral bone marrow lesions. Eur J Radiol. 2009;69:560-6.

60. Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: A quantitative parameter for in vivo tumor characterization. Eur J Radiol. 2003;45:208-13.

61. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR Imaging in cancer: Current status and research directions. Radiology. 2011;261:700-18.

62. Koh DM, Collins D. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188:1622-35.

63. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): Technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275-82.

64. Nakanishi K, Kobayashi M, Nakaguchi K, et al. Whole-body MRI for detecting metastatic bone tumor: Diagnostic value of diffusion- weighted images. Magn Reson Med Sci. 2007;6:147-55.

65. Kwee TC, Takahara T, Ochiai K, et al. Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol. 2009;70:409-17.

66. Balach T, Stacy GS, Peabody TD. The clinical evaluation of bone tumors. Radiol Clin N Am. 2011;49:1079-93.

67. Huang AJ, Kattapuram SV. Musculoskeletal neoplasms: Biopsy and intervention. Radiol Clin N Am. 2011;49:1287-305.

68. Jelinek JS, Murphey MD, Welker JA, et al. Diagnosis of primary bone tumors with image-guided percutaneous biopsy: Experience with 110 tumors. Radiology. 2002;223:731-7.

69. Coleman RE. Management of bone metastases. Oncologist. 2000;5:463-70.

70. Vassiliou V. Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: Effectiveness and safety. Clin Oncol (R Coll Radiol). 2013;25:290-7.

71. Blum RH, Novetsky D, Shasha D, Fleishman S. The multidisciplinary approach to bone metastases. Oncology. 2003;17:845-67.

72. Fizazi K, Carducci M, Smith M, et al. Denosumab versus Zoledronic acid for treatment of bone metastases in men with castration- resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377:813-22.

73. Kurata T, Nakagawa K. Efficacy and safety of Denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol. 2012;42:663-9.

74. Baron R, Ferrari S, Rusell RGG. Review. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011;48:677-92.

75. Peddi P, Lopez-Olivo MA. Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97-104.

76. Singh K, Samartzis D, Vaccaro AR, et al. Current concepts in the management of metastatic spinal disease: The role of minimally- invasive approaches. J Bone Joint Surg Br. 2006;88:434-42.

77. Rades D. Dose-fractionation schedules for radiotherapy of bone metastases. Breast Care. 2010;5:339-44.

78. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Nat Cancer Inst. 2005;97:798-804.

79. Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: review of current treatment options. CA Cancer J Clin. 2008;58:245-59.

80. Maisano R, Pergolizzi S, Cascinu S. Novel therapeutic approaches to cancer patients with bone metastases. Crit Rev Oncol Hematol. 2001;40:239-50.

81. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(Suppl 1):38-47S.

82. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358-65.

83. Peh WC, Munk PL, Rashid F, et al. Percutaneous vertebral augmentation: Vertebroplasty, kyphoplasty and kyphoplasty. Radiol Clin N Am. 2008;46:611-35.

84. Shimony JS, Gilula LA, Zeller AJ, et al. Percutaneous vertebroplasty for malignant compression fractures with epidural involvement. Radiology. 2004;232:846-53.

85. Hurley MC, Kaakaji R, Dabus G, et al. Percutaneous vertebroplasty. Neurosurg Clin N Am. 2009;20:341-59.

86. Shaibani A, Ali S, Bhatt H. Vertebroplasty and kyphoplasty for the palliation of pain. Semin Intervent Radiol. 2007;24:409-18.

87. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 2003;98(Suppl 1):21-30.

88. Barragán-Campos HM, Le Faou AL, Rose M, et al. Percutaneous vertebroplasty in vertebral metastases from breast cancer: Interest in terms of pain relief and quality of life. Interv Neuroradiol. 2014;20:591-602.

89. Peh WC, Gilula LA. Percutaneous vertebroplasty: Indications, contraindications, and technique. Brit J Radiol. 2003;76:69-75.

90. Ward E, Munk PL, Rashid F, et al. Musculoskeletal interventional radiology: radiofrequency ablation. Radiol Clin N Am. 2008;46:599-610.

91. Thanos L, Mylona S, Galani P, et al. Radiofrequency ablation of osseous metastases for the palliation of pain. Skeletal Radiol. 2008;37:189-94.

92. Kassamali RH, Ganeshan A, Hoey ET, et al. Pain management in spinal metastases: The role of percutaneous vertebral augmentation. Ann Oncol. 2011;22:782-6.

93. Palussière J, Pellerin-Guignard A, Descat E, et al. Radiofrequency ablation of bone tumours. Diagn Interv Imaging. 2012;93:660-4.

94. Gangi A, Basile A, Buy X, et al. Radiofrequency and laser ablation of spinal lesions. Semin Ultrasound CT MR. 2005;26:89-97.

95. Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine. 2005;30:2186-91.

96. Wood S, Brown JE. Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treat Rev. 2011;38:284-91.

97. Imkampe A, Bendall S, Bates T. The significance of the site of recurrence to subsequent breast cancer survival. Eur J Surg Oncol. 2007;33:420-3.

98. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-6.

99. Shack L, Bryant H, Lockwood G. et al. Conditional relative survival: a different perspective to measuring cancer outcomes. Cancer Epidemiol. 2013;37:446-8.

100. Yong M, Jensen AO, Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: A population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011;129:495-503.

101. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784-96.

102. Shen Z, Xie H, Wang C, et al. Clinical features and management of prostate cancer with bone metastases: the first report of our institute. Chin Ger J Clin Oncol. 2008;7:590-2.

103. Nieder C, Haukland E, Pawinski A, et al. Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases. BMC Urol. 2010;10:1-7.

104. Norgaard M, Jensen AO, Jacobsen JB, et al. Skeletal related events, bone metastases and survival of prostate cancer: A population-based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162-7.

105. Saindane AM. Pitfalls in the staging of cancer of thyroid. Neuroimag Clin N Am. 2013;23:123-45.

106. Voutilainen PE, Multanen M, Haapiainen RK, et al. Anaplastic thyroid carcinoma survival. World J Surg. 1999;23:975-9.

107. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007. Available at: http://seer.cancer.gov/archive/ csr/1975_2007/.

108. Orita Y, Sugitani I, Matsuura M, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery. 2010;147:424-31.

109. Kuchuk M, Addison CL, Clemons M, et al. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol. 2013;2:22-9.

110. Beckett P, Tata LJ, Hubbard RB. Risk factors and survival outcome for non-elective referral in non-small cell lung cancer patients. Analysis based on the National Lung Cancer Audit. Lung Cancer. 2014;83:396-400.

111. Bae HM, Lee SH, Kim TM, et al. Prognostic factors from nonsmall cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer. 2012;77:572-7.

112. Spizzo G, Seeber A, Mitterer M. Routine use of Pamidronate in NSCLC patients with bone metastases: Results from retrospective analysis. Anticancer Res. 2009;29:5245-9.

113. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29-55S.

114. Hubbard MO, Fu P, Margevicius S, et al. Five-year survival does not equal cure in non–small cell lung cancer: A surveillance, epidemiology, and end results–based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg. 2012;143:1307-12.

115. Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2003;8:541-52.

116. Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011;48:160-6.

117. Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Français d´Immunothérapie. Ann Oncol. 2002;13:1460-8.

118. Toyoda Y, Shinohara N, Harabayashi T, et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52:163-9.

119. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-40.

120. Bhagat S, Sharma H, Graham J, et al. Current concepts in the management of renal osseous metastases. Orthopaedics Trauma. 2010;24:363-8.

121. Drucker B. Prognostic factors for biologic therapy in kidney cancer. Curr Urol Rep. 2002;3:31-6.